Breast Cancer
Each woman’s risk of developing breast cancer is different and depends on her lifestyle, family health history, and other factors. The American Cancer Society considers women who have a lifetime risk assessment of 20% or greater to be at high risk for breast cancer.
The authors present their findings from a study testing the effects of an early intervention by the Breast Cancer Navigator on distress.
Transitions in care require well-managed timing and sequencing of events across specialties.
The combination of the mammalian target of rapamycin (mTOR) inhibitor, everolimus, and the aromatase inhibitor, exemestane, is approved for use in postmenopausal women with HR+, HER2– ABC after failure on letrozole or anastrozole treatment.
Endocrine therapy is recommended for patients with hormone receptor–positive (HR+) advanced and metastatic breast cancer without visceral crisis (symptomatic visceral disease).
Breast cancer occurs predominantly in older, postmenopausal women (>50 years), although the incidence of ABC in younger, premenopausal women is increasing.
To honor our connection to the field of breast cancer, we dedicate a special annual edition of JONS to breast cancer and the strides being made in the treatment of this disease as part of our Best Practices series.
A breast cancer diagnosis can be difficult for women of any age, but young women can have unique needs that make this experience more complex.
A breast nurse navigator can perform patient-centered education on breast cancer type and possible treatment options using the inclusive pathology report, as well as be available during the disease trajectory to proactively guide the patient with additional education and support.
A case study describing the course and outcomes of treatment, the real-life challenges that arise when attempting to utilize a manualized treatment, and the unique factors that contribute to this case.
© 2009- DBA AONN+ Academy of Oncology Nurse & Patient Navigators® PO Box 563, Cranbury, NJ 08512